TY - JOUR
T1 - Convergent Validity of Suffering and Quality of Life as Measured by The Hidradenitis Suppurativa Quality of Life
AU - Kursawe Larsen, C.
AU - Kjærsgaard Andersen, R.
AU - Kirby, J. S.
AU - Tan, J.
AU - Saunte, D. M.L.
AU - Jemec, G. B.E.
N1 - Funding Information:
Mr. Larsen and Dr. Kjærsgaard Andersen have nothing to disclose. Dr. Kirby reports personal fees from AbbVie, personal fees from ChemoCentryx, personal fees from Incyte, personal fees from Novartis, personal fees from Janssen, personal fees from UCB Pharma, outside the submitted work. In addition, Dr. Kirby has a patent HiSQOL with royalties paid to Penn State University. Dr. Tan reports grants from Abbvie, grants from UCB, personal fees from UCB, outside the submitted work. Dr. Saunte reports personal fees from AbbVie, personal fees from Janssen, personal fees from Sanofi, personal fees from Leo Pharma, grants and personal fees from Abbvie, personal fees from Leo Pharma, grants from Novartis, personal fees from Jansen, outside the submitted work. Dr. Jemec reports grants and personal fees from Abbvie, personal fees from Coloplast, personal fees from Chemocentryx, personal fees from LEO pharma, grants from LEO Foundation, grants from Afyx, personal fees from Incyte, grants and personal fees from InflaRx, grants from Janssen‐Cilag, grants and personal fees from Novartis, grants and personal fees from UCB, grants from CSL Behring, grants from Regeneron, grants from Sanofi, personal fees from Kymera, personal fees from VielaBio, outside the submitted work.
Publisher Copyright:
© 2021 European Academy of Dermatology and Venereology
PY - 2021/7
Y1 - 2021/7
N2 - Background: Hidradenitis suppurativa (HS) is a painful chronic, recurrent inflammatory skin disease with great impact on health-related quality of life (HRQOL). Recently, Hidradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC) established HRQOL as a core domain set for HS clinical trials and developed the Hidradenitis Suppurativa Quality of Life (HiSQOL) as a validated outcome measurement instrument. Objectives: To provide further convergent validity of HiSQOL by comparing it to Dermatology Life Quality Index (DLQI) and Pictorial Representation of Illness and Self Measure-Revised 2 (PRISM-R2). Methods: In this cross-sectional study, 103 participants completed HiSQOL, PRISM-R2 and DLQI. PRISM-R2 is an instrument designed to measure suffering and reports the two measures, Illness Perception Measure (IPM) and Self-Illness Separation (SIS). Correlation analyses were performed including a sub-analysis for a subgroup of patients with high scores in the HS-specific domains of HiSQOL. Results: A very strong correlation was found between HiSQOL and DLQI (ρ = 0.93, P < 2.2 × 10−16, (95% CI: 0.89;0.95)), and moderately strong correlations were found between HiSQOL and SIS (ρ = −0.73, P < 2.2 × 10−16, (95% CI: −0.81; −0.62)) and DLQI and SIS (ρ = −0.70, P < 2.2 × 10−16, (95% CI: −0.79; −0.59)). IPM was positively associated with HiSQOL and DLQI and negatively with SIS. Conclusions: HiSQOL is a valid measure of quality of life for HS patients, and we suggest that HiSQOL can be used as a measure of suffering as well.
AB - Background: Hidradenitis suppurativa (HS) is a painful chronic, recurrent inflammatory skin disease with great impact on health-related quality of life (HRQOL). Recently, Hidradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC) established HRQOL as a core domain set for HS clinical trials and developed the Hidradenitis Suppurativa Quality of Life (HiSQOL) as a validated outcome measurement instrument. Objectives: To provide further convergent validity of HiSQOL by comparing it to Dermatology Life Quality Index (DLQI) and Pictorial Representation of Illness and Self Measure-Revised 2 (PRISM-R2). Methods: In this cross-sectional study, 103 participants completed HiSQOL, PRISM-R2 and DLQI. PRISM-R2 is an instrument designed to measure suffering and reports the two measures, Illness Perception Measure (IPM) and Self-Illness Separation (SIS). Correlation analyses were performed including a sub-analysis for a subgroup of patients with high scores in the HS-specific domains of HiSQOL. Results: A very strong correlation was found between HiSQOL and DLQI (ρ = 0.93, P < 2.2 × 10−16, (95% CI: 0.89;0.95)), and moderately strong correlations were found between HiSQOL and SIS (ρ = −0.73, P < 2.2 × 10−16, (95% CI: −0.81; −0.62)) and DLQI and SIS (ρ = −0.70, P < 2.2 × 10−16, (95% CI: −0.79; −0.59)). IPM was positively associated with HiSQOL and DLQI and negatively with SIS. Conclusions: HiSQOL is a valid measure of quality of life for HS patients, and we suggest that HiSQOL can be used as a measure of suffering as well.
UR - http://www.scopus.com/inward/record.url?scp=85101887983&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101887983&partnerID=8YFLogxK
U2 - 10.1111/jdv.17148
DO - 10.1111/jdv.17148
M3 - Article
C2 - 33539563
AN - SCOPUS:85101887983
SN - 0926-9959
VL - 35
SP - 1577
EP - 1581
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
IS - 7
ER -